Pharmacokinetic Evaluation of a Fixed‐Dose Combination of Pelubiprofen and Tramadol: A Randomized Crossover Relative Bioavailability Trial and a Fixed‐Sequence Food‐Effect Study in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026-03 · 15 (3)
DOI: 10.1002/cpdd.70050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 12.03.2026. Verfasst von Bui Thi Tham und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Trial and Bioequivalence Study, Faculty of Pharmacy, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam. Hauptthemen laut MEDLINE: Tramadol, Food-Drug Interactions, Analgesics, Opioid, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Daewon Pharm. Co., Ltd.
Abstract (Originalsprache)
DW‐1021 is a novel fixed‐dose combination salt formulation containing pelubiprofen 45 mg and tramadol hydrochloride 45.9 mg (equivalent to 40.3 mg tramadol free base). Two open‐label, phase I clinical studies were conducted in healthy Vietnamese male volunteers to characterize the pharmacokinetics of DW‐1021. The relative bioavailability study employed a randomized, single‐dose, two‐period, two‐sequence crossover design (n = 14) comparing DW‐1021 with co‐administration of Pelubi CR (pelubiprofen 45 mg) and Zytram CR (tramadol hydrochloride 75 mg, equivalent to 65.9 mg tramadol base) under fasting conditions. The food effect study used a fixed‐sequence, two‐period design (n = 14) to evaluate DW‐1021 under fasting and fed (high‐fat, high‐calorie) conditions. In the relative bioavailability study, DW‐1021 resulted in lower exposure to pelubiprofen (AUC 0‐t GMR: 86.68%) and generally comparable exposure to trans‐OH‐pelubiprofen (AUC 0‐t GMR: 108.74%) compared with the reference treatment. For tramadol, unadjusted comparisons showed a higher peak concentration (C max GMR: 192.17%) but lower overall exposure (AUC 0‐t GMR: 79.30%). After dose normalization, tramadol exposure per unit dose was higher (AUC 0‐t /Dose GMR: 129.58%). In the food effect study, fasting conditions were associated with higher C max and AUC 0‐t of pelubiprofen (GMRs: 109.92% and 140.48%, respectively). Food increased tramadol C max , while AUC 0‐t remained largely comparable between conditions. All adverse events were mild to moderate, and no serious adverse events were reported. In conclusion, DW‐1021 exhibited analyte‐dependent pharmacokinetic differences relative to the reference treatment. Food intake primarily reduced pelubiprofen exposure, while tramadol AUC 0‐t was minimally affected, with a modest increase in C max under fed conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Clinical Trial and Bioequivalence Study, Faculty of Pharmacy, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
- Department of Pharmacy, Hai Phong International Hospital, Hai Phong, Vietnam.
- Office of the CEO, Aimedisurvey Company, Singapore.
- R&D Division, Daewon Pharm. Co., Ltd., Seongdong-gu, Seoul, Republic of Korea.
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Förderung
- Daewon Pharm. Co., Ltd
Zitieren
APA
Tham, B. T., Ngan, T. T., Van Anh, T., Chool, K. D., Ram, L. A., Wook, P. S., Bok, L. S., Ho, O. D., Van Khai, N., & Phuong, N. T. T. (2026). Pharmacokinetic Evaluation of a Fixed‐Dose Combination of Pelubiprofen and Tramadol: A Randomized Crossover Relative Bioavailability Trial and a Fixed‐Sequence Food‐Effect Study in Healthy Volunteers. Clinical Pharmacology in Drug Development, 15(3). https://doi.org/10.1002/cpdd.70050
Vancouver
Tham BT, Ngan TT, Van Anh T, Chool KD, Ram LA, Wook PS, et al. Pharmacokinetic Evaluation of a Fixed‐Dose Combination of Pelubiprofen and Tramadol: A Randomized Crossover Relative Bioavailability Trial and a Fixed‐Sequence Food‐Effect Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026;15(3). doi:10.1002/cpdd.70050
BibTeX
@article{Tham2026,
author = {Tham, Bui Thi and Ngan, Tran Thi and Van Anh, Tran and Chool, Kim Dong and Ram, Lee Ah and Wook, Park Sang and Bok, Lee Soo and Ho, Oh Dong and Van Khai, Nguyen and Phuong, Nguyen Thi Thu},
title = {Pharmacokinetic Evaluation of a Fixed‐Dose Combination of Pelubiprofen and Tramadol: A Randomized Crossover Relative Bioavailability Trial and a Fixed‐Sequence Food‐Effect Study in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cpdd.70050}
}
EUVIMED